Literature DB >> 21725649

[Therapy-refractory overactive bladder: alternative treatment approaches].

S Knüpfer1, M Hamann, C M Naumann, D Melchior, K-P Jünemann.   

Abstract

The treatment of patients with overactive bladder (OAB) refractory to conventional treatment is gaining clinical significance. This article intends to review alternative therapy options for patients with OAB refractory to conventional treatment. A search of the PubMed database as well as the abstracts presented at the European Association of Urology and the American Urological Association annual meetings was conducted. Keywords used during this search included overactive bladder (OAB) refractory to conventional treatment, electromotive drug administration (EMDA), sacral neuromodulation, augmentation cystoplasty and cystectomy. Eighteen articles with an adequate number of patients were identified. All articles published before 2001 were not included in this analysis. Because of first-line treatment failure, 30% of the patients required alternative treatment. This included EMDA, botulinum toxin injections into the detrusor, sacral neuromodulation, augmentation cystoplasty or cystectomy. Based on this review it appears that a significant improvement in micturition parameters, continence and in quality of life was achieved. Overall EMDA, intradetrusor injections of botulinum toxin and sacral neuromodulation seem to be highly effective and safe. Augmentation cystoplasty or cystectomy remains the last choice of treatment in refractory cases.Overall EMDA, intradetrusor injections of botulinum toxin and sacral neuromodulation seem to be highly effective and safe. Augmentation cystoplasty or cystectomy remains to be the last choice of treatment in refractory cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21725649     DOI: 10.1007/s00120-011-2609-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  11 in total

Review 1.  Botulinum toxin--mechanisms of action and clinical use in spasticity.

Authors:  Michael Barnes
Journal:  J Rehabil Med       Date:  2003-05       Impact factor: 2.912

2.  Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland.

Authors:  Thomas M Kessler; Eric Buchser; Sylvain Meyer; Daniel S Engeler; Abdul-Wahab Al-Khodairy; Ulf Bersch; Christophe E Iselin; Bruno Roche; Daniel M Schmid; Brigitte Schurch; Stephane Zrehen; Fiona C Burkhard
Journal:  Eur Urol       Date:  2006-11-13       Impact factor: 20.096

3.  Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.

Authors:  D M Schmid; P Sauermann; M Werner; B Schuessler; N Blick; M Muentener; R T Strebel; D Perucchini; D Scheiner; G Schaer; H John; A Reitz; D Hauri; B Schurch
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

4.  Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study.

Authors:  A C van Voskuilen; D J A J Oerlemans; E H J Weil; R A de Bie; Ph E V A van Kerrebroeck
Journal:  Eur Urol       Date:  2006-01-04       Impact factor: 20.096

5.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

6.  [Effects of botulinum toxin type A in the single and repeated treatment of overactive bladder. A prospective analysis].

Authors:  C Frohme; Z Varga; P Olbert; A J Schrader; R Hofmann; A Hegele
Journal:  Urologe A       Date:  2010-05       Impact factor: 0.639

7.  Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation.

Authors:  U Jonas; C J Fowler; M B Chancellor; M M Elhilali; M Fall; J B Gajewski; V Grünewald; M M Hassouna; U Hombergh; R Janknegt; P E van Kerrebroeck; A A Lylcklama a Nijeholt; S W Siegel; R A Schmidt
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

8.  The prevalence of urinary incontinence in women in four European countries.

Authors:  S Hunskaar; G Lose; D Sykes; S Voss
Journal:  BJU Int       Date:  2004-02       Impact factor: 5.588

9.  Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity.

Authors:  Peter Bach; Renate T Wormland; Cornelia Möhring; Mark Goepel
Journal:  Neurourol Urodyn       Date:  2009       Impact factor: 2.696

10.  Electromotive drug administration for treatment of therapy-refractory overactive bladder.

Authors:  A Gauruder-Burmester; A Biskupskie; A Rosahl; R Tunn
Journal:  Int Braz J Urol       Date:  2008 Nov-Dec       Impact factor: 1.541

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.